AstraZeneca divests global rights to Movantik

25 February 2020 07:00 GMT

License to RedHill Biopharma supports AstraZeneca’s focus on main therapy areas

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik365备用网址APP is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope to enable reinvestment in our main therapy areas. Movantik365备用网址APP is an important established medicine and the divestment to RedHill will ensure its continued availability for patients.”

As part of the agreement, AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik365备用网址APP in the US, which will be transferred to RedHill.

Financial considerations

RedHill will make an upfront payment of $52.5m to AstraZeneca on closing and a further non-contingent payment of $15m in 2021. Income arising from the upfront payment, offset by a charge for derecognition of the associated intangible asset, and the future payment will be reported in AstraZeneca’s financial statements within Other Operating Income & Expense. In 2019, Movantik 365备用网址APPgenerated sales of $96m in the US. The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. Upon completion, the agreement will not impact the Company’s financial guidance for 2020.


Movantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic non-cancer pain. Movantik was licensed from Nektar Therapeutics in 2009. It was developed using Nektar’s oral small-molecule polymer conjugate technology. In 2016, AstraZeneca divested the rights in Europe to ProStrakan Group (now KKI) and the rights in Canada and Israel to Knight Therapeutics.


AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @.



Media Relations



365备用网址APPGonzalo Viña


+44 203 749 5916

365备用网址APPRob Skelding


+44 203 749 5821

365备用网址APPRebecca Einhorn


+1 301 518 4122

Matt Kent


+44 203 749 5906

365备用网址APPAngela Fiorin


365备用网址APP+44 1223 344 690

Jennifer Hursit


365备用网址APP+44 203 749 5762

Christina Malmberg Hägerstrand


365备用网址APP+46 8 552 53 106

365备用网址APPMichele Meixell


+1 302 885 2677


Investor Relations



Thomas Kudsk Larsen


365备用网址APP+44 203 749 5712

365备用网址APPHenry Wheeler


365备用网址APP+44 203 749 5797

365备用网址APPChrister Gruvris


(Cardiovascular, Metabolism)

365备用网址APP+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

365备用网址APPJosie Afolabi

BioPharmaceuticals (Respiratory)

+44 203 749 5631

365备用网址APPTom Waldron

Other medicines

+44 7385 033 717

Craig Marks


365备用网址APPFixed income

365备用网址APP+44 7881 615 764

Jennifer Kretzmann

365备用网址APPCorporate access

365备用网址APPRetail investors

365备用网址APP+44 203 749 5824

365备用网址APPUS toll-free


365备用网址APP+1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC



  • Corporate and financial
  • Partnering